Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics

A Kirtonia, K Gala, SG Fernandes, G Pandya… - Seminars in cancer …, 2021 - Elsevier
Human malignancies are one of the major health-related issues though out the world and
anticipated to rise in the future. The development of novel drugs/agents requires a huge …

The renin–angiotensin system and cancer: old dog, new tricks

AJ George, WG Thomas, RD Hannan - Nature Reviews Cancer, 2010 - nature.com
For cancers to develop, sustain and spread, the appropriation of key homeostatic
physiological systems that influence cell growth, migration and death, as well as …

Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention

F Masoudkabir, N Sarrafzadegan, C Gotay… - Atherosclerosis, 2017 - Elsevier
Cardiovascular disease (CVD) and cancer are leading causes of mortality and morbidity
worldwide. Strategies to improve their treatment and prevention are global priorities and …

Repurposing drugs targeting metabolic diseases for cancer therapeutics

J Pillai, A Ray, M Maan, M Dutta - Drug Discovery Today, 2023 - Elsevier
Highlights•Discovery of new drugs against cancer is of utmost importance.•Drug repurposing
is an alternative approach to traditional drug discovery.•It significantly reduces the R&D …

Anticancer potential of animal venoms and toxins

A Gomes, P Bhattacharjee, R Mishra, AK Biswas… - 2010 - nopr.niscpr.res.in
Anticancer drug development from natural resources are ventured throughout the world.
Animal venoms and toxins a potential bio resource and a therapeutic tool were known to …

[HTML][HTML] CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline …

RE Kast, G Karpel-Massler, ME Halatsch - Oncotarget, 2014 - ncbi.nlm.nih.gov
CUSP9 treatment protocol for recurrent glioblastoma was published one year ago. We now
present a slight modification, designated CUSP9*. CUSP9* drugs-aprepitant, artesunate …

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer …

S Wilop, S von Hobe, M Crysandt, A Esser… - Journal of cancer …, 2009 - Springer
Purpose The renin-angiotensin system plays a crucial role in maintaining vascular
homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by …

Repurposing of chronically used drugs in cancer therapy: a chance to grasp

MA Hijazi, A Gessner, N El-Najjar - Cancers, 2023 - mdpi.com
Simple Summary Cancer mortalities are growing at an alarming pace around the globe, a
fact related to challenges, such as side effects, selectivity, and resistance, accompanied by …

The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer

Y Feng, H Wan, J Liu, R Zhang, Q Ma… - Oncology …, 2010 - spandidos-publications.com
Angiotensin II (AngII) is a multifunctional bioactive peptide and previous studies have shown
that the renin-angiotensin system (RAS) of both host and tumor are important in tumor …

Renin-angiotensin system in lung tumor and microenvironment interactions

MJ Catarata, R Ribeiro, MJ Oliveira, C Robalo Cordeiro… - Cancers, 2020 - mdpi.com
The mechanistic involvement of the renin-angiotensin system (RAS) reaches beyond
cardiovascular physiopathology. Recent knowledge pinpoints a pleiotropic role for this …